MA52595B1 - Formulation liquide stable de gonadotrophines - Google Patents
Formulation liquide stable de gonadotrophinesInfo
- Publication number
- MA52595B1 MA52595B1 MA52595A MA52595A MA52595B1 MA 52595 B1 MA52595 B1 MA 52595B1 MA 52595 A MA52595 A MA 52595A MA 52595 A MA52595 A MA 52595A MA 52595 B1 MA52595 B1 MA 52595B1
- Authority
- MA
- Morocco
- Prior art keywords
- gonadotrophins
- liquid formulation
- stable liquid
- stabilization
- formulation
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 102000006771 Gonadotropins Human genes 0.000 abstract 2
- 108010086677 Gonadotropins Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002622 gonadotropin Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940094892 gonadotropins Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne de manière générale le domaine de la stabilisation de formulations de gonadotrophines, en particulier de formulations liquides de gonadotrophines. La stabilisation est obtenue grâce à une combinaison particulière d'excipients, de préférence l'arginine et la méthionine. Dans un mode de réalisation préféré, la formulation ne comprend pas de tampon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603280.7A GB201603280D0 (en) | 2016-02-24 | 2016-02-24 | Stable liquid gonadotropin formulation |
| PCT/EP2017/054325 WO2017144659A1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52595A MA52595A (fr) | 2021-03-17 |
| MA52595B1 true MA52595B1 (fr) | 2023-12-29 |
Family
ID=55806922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43686A MA43686B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
| MA52595A MA52595B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43686A MA43686B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10792334B2 (fr) |
| EP (3) | EP3791860B1 (fr) |
| JP (3) | JP6932710B2 (fr) |
| KR (1) | KR102756413B1 (fr) |
| CN (2) | CN108883061B (fr) |
| AR (1) | AR107782A1 (fr) |
| AU (2) | AU2017222292B2 (fr) |
| BR (1) | BR112018015166A2 (fr) |
| CA (1) | CA3012759A1 (fr) |
| CL (1) | CL2018001984A1 (fr) |
| CO (1) | CO2018007810A2 (fr) |
| DK (2) | DK3419595T3 (fr) |
| EA (1) | EA036383B1 (fr) |
| ES (2) | ES2862193T3 (fr) |
| FI (1) | FI3791860T3 (fr) |
| GB (1) | GB201603280D0 (fr) |
| HR (2) | HRP20210367T1 (fr) |
| HU (2) | HUE064432T2 (fr) |
| IL (1) | IL260626B2 (fr) |
| JO (1) | JOP20170046B1 (fr) |
| LT (2) | LT3791860T (fr) |
| MA (2) | MA43686B1 (fr) |
| MD (2) | MD3791860T2 (fr) |
| MX (1) | MX381709B (fr) |
| MY (1) | MY193138A (fr) |
| PH (1) | PH12018501688B1 (fr) |
| PL (2) | PL3791860T3 (fr) |
| PT (2) | PT3419595T (fr) |
| RS (2) | RS64929B1 (fr) |
| SG (1) | SG11201806140SA (fr) |
| SI (2) | SI3791860T1 (fr) |
| TN (1) | TN2018000284A1 (fr) |
| TW (1) | TWI755377B (fr) |
| UA (1) | UA123107C2 (fr) |
| WO (1) | WO2017144659A1 (fr) |
| ZA (1) | ZA201804944B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| WO2019164765A1 (fr) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Compositions de dexmédétomidine prêtes à l'emploi |
| BR112021006406A2 (pt) * | 2018-10-02 | 2021-07-06 | Innocore Tech Holding B V | forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada |
| CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| WO2022197963A1 (fr) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Compositions d'hormone de croissance à action prolongée |
| CN118209739A (zh) * | 2024-03-19 | 2024-06-18 | 厦门宝太和瑞生物技术有限公司 | 促黄体生成素检测试剂盒 |
| KR102821987B1 (ko) * | 2024-10-24 | 2025-06-26 | 에이디텍 주식회사 | 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2198299C (fr) | 1996-02-28 | 2000-05-02 | Yuhei Abe | Afficheur de solde genre porte-carte |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| CA2335340C (fr) * | 1998-07-23 | 2013-03-05 | Eli Lilly And Company | Formulations de fsh et de variants de fsh, produits et procedes |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| ES2393233T3 (es) * | 2007-11-01 | 2012-12-19 | Merck Serono S.A. | Formulaciones de LH líquidas |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RS52106B (sr) | 2008-02-08 | 2012-08-31 | Biogenerix Ag | Tečni preparat fsh |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| RU2561057C2 (ru) | 2008-11-04 | 2015-08-20 | Аска Фармасьютикал Ко., Лтд. | Водная композиция, содержащая фолликулостимулирующий гормон |
| RU2553375C2 (ru) | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
| WO2011108010A2 (fr) | 2010-03-05 | 2011-09-09 | Intas Biopharmaceuticals Limited | Préparation liquide thermostable de gonadotropines |
| EP2417982A1 (fr) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilisation de gonadotrophines |
| HK1223559A1 (zh) * | 2013-11-12 | 2017-08-04 | Cadila Healthcare Limited | 用於促性腺激素的配方 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
-
2016
- 2016-02-24 GB GBGB1603280.7A patent/GB201603280D0/en not_active Ceased
-
2017
- 2017-02-19 JO JOP/2017/0046A patent/JOP20170046B1/ar active
- 2017-02-23 TW TW106106132A patent/TWI755377B/zh active
- 2017-02-24 PL PL20202758.7T patent/PL3791860T3/pl unknown
- 2017-02-24 MD MDE20210250T patent/MD3791860T2/ro unknown
- 2017-02-24 PH PH1/2018/501688A patent/PH12018501688B1/en unknown
- 2017-02-24 ES ES17707527T patent/ES2862193T3/es active Active
- 2017-02-24 EP EP20202758.7A patent/EP3791860B1/fr active Active
- 2017-02-24 SG SG11201806140SA patent/SG11201806140SA/en unknown
- 2017-02-24 SI SI201731448T patent/SI3791860T1/sl unknown
- 2017-02-24 RS RS20231172A patent/RS64929B1/sr unknown
- 2017-02-24 CA CA3012759A patent/CA3012759A1/fr active Pending
- 2017-02-24 EA EA201891905A patent/EA036383B1/ru not_active IP Right Cessation
- 2017-02-24 PT PT177075272T patent/PT3419595T/pt unknown
- 2017-02-24 HU HUE20202758A patent/HUE064432T2/hu unknown
- 2017-02-24 HR HRP20210367TT patent/HRP20210367T1/hr unknown
- 2017-02-24 SI SI201730666T patent/SI3419595T1/sl unknown
- 2017-02-24 EP EP23194814.2A patent/EP4257149A3/fr not_active Withdrawn
- 2017-02-24 MX MX2018010201A patent/MX381709B/es unknown
- 2017-02-24 KR KR1020187027128A patent/KR102756413B1/ko active Active
- 2017-02-24 MD MDE20190039T patent/MD3419595T2/ro unknown
- 2017-02-24 ES ES20202758T patent/ES2966262T3/es active Active
- 2017-02-24 UA UAA201809497A patent/UA123107C2/uk unknown
- 2017-02-24 LT LTEP20202758.7T patent/LT3791860T/lt unknown
- 2017-02-24 EP EP17707527.2A patent/EP3419595B1/fr active Active
- 2017-02-24 TN TNP/2018/000284A patent/TN2018000284A1/en unknown
- 2017-02-24 PL PL17707527T patent/PL3419595T3/pl unknown
- 2017-02-24 US US16/079,428 patent/US10792334B2/en active Active
- 2017-02-24 BR BR112018015166-1A patent/BR112018015166A2/en active Search and Examination
- 2017-02-24 DK DK17707527.2T patent/DK3419595T3/da active
- 2017-02-24 JP JP2018544561A patent/JP6932710B2/ja active Active
- 2017-02-24 MA MA43686A patent/MA43686B1/fr unknown
- 2017-02-24 PT PT202027587T patent/PT3791860T/pt unknown
- 2017-02-24 CN CN201780013134.9A patent/CN108883061B/zh active Active
- 2017-02-24 CN CN202110585922.3A patent/CN113398250B/zh active Active
- 2017-02-24 AR ARP170100475A patent/AR107782A1/es not_active Application Discontinuation
- 2017-02-24 WO PCT/EP2017/054325 patent/WO2017144659A1/fr not_active Ceased
- 2017-02-24 AU AU2017222292A patent/AU2017222292B2/en active Active
- 2017-02-24 HU HUE17707527A patent/HUE053492T2/hu unknown
- 2017-02-24 MY MYPI2018001301A patent/MY193138A/en unknown
- 2017-02-24 DK DK20202758.7T patent/DK3791860T5/da active
- 2017-02-24 RS RS20210361A patent/RS61604B1/sr unknown
- 2017-02-24 LT LTEP17707527.2T patent/LT3419595T/lt unknown
- 2017-02-24 MA MA52595A patent/MA52595B1/fr unknown
- 2017-02-24 HR HRP20231477TT patent/HRP20231477T1/hr unknown
- 2017-02-24 FI FIEP20202758.7T patent/FI3791860T3/fi active
-
2018
- 2018-07-17 IL IL260626A patent/IL260626B2/en unknown
- 2018-07-23 ZA ZA2018/04944A patent/ZA201804944B/en unknown
- 2018-07-23 CL CL2018001984A patent/CL2018001984A1/es unknown
- 2018-07-27 CO CONC2018/0007810A patent/CO2018007810A2/es unknown
-
2020
- 2020-09-14 US US17/020,279 patent/US11666635B2/en active Active
-
2021
- 2021-08-18 JP JP2021133422A patent/JP2021191760A/ja active Pending
-
2022
- 2022-01-05 AU AU2022200027A patent/AU2022200027A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/138,000 patent/US12447196B2/en active Active
- 2023-09-15 JP JP2023150308A patent/JP2023164573A/ja active Pending
-
2025
- 2025-04-02 US US19/098,420 patent/US20250352621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43686A (fr) | Formulation liquide stable de gonadotrophines | |
| TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
| MX2021003455A (es) | Lípidos con amina ionizables. | |
| MX2021006150A (es) | Lípidos con amina modificados. | |
| WO2014066468A8 (fr) | Formulation d'anticorps, stable, à faible viscosité | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| NI201200119A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina - 6 (il -6r) | |
| TN2018000443A1 (en) | Stable liquid pharmaceutical preparation | |
| EA201490801A1 (ru) | Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов | |
| EP4684797A3 (fr) | Solution proteinique stable contenant une haute concentration de anti-vegf anticorps | |
| UY27854A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| MX2012002861A (es) | Formulaciones farmaceuticas muy concentradas. | |
| CL2017003208A1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| PH12020551500A1 (en) | Viscosity reduction of highly concentrated protein formulations | |
| EA200970274A1 (ru) | Способы введения гипогликемических средств с длительным действием | |
| EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| MX2021014310A (es) | Formulaciones de terlipressina. | |
| EA201070378A1 (ru) | Фармацевтические составы орлистата | |
| CO2023000239A2 (es) | Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas | |
| PH12022550238A1 (en) | Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations | |
| CO2021000763A2 (es) | Estabilidad de la vitamina d en b-hidroxi- b-metilbutirato(hmb) | |
| UY37260A (es) | Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón | |
| MY194758A (en) | Stable liquid pharmaceutical formulation |